Drug Type Small molecule drug |
Synonyms Adapalene-Clindamycin, Adapalene/clindamycin, Clindamycin/adapalene + [3] |
Target |
Action inhibitors, agonists |
Mechanism 50S subunit inhibitors(50S ribosomal subunit inhibitors), RARs agonists(Retinoic acid receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (20 Feb 2024), |
Regulation- |
Molecular FormulaC18H34Cl2N2O5S |
InChIKeyAUODDLQVRAJAJM-XJQDNNTCSA-N |
CAS Registry21462-39-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acne Vulgaris | China | 20 Feb 2024 |
Phase 3 | 1,617 | Adapalene/Clindamycin(5mg/50mg) | ysxfcxgvwi(lklwmuyrnd) = vgphaecehi ilwrgfjymi (kobfodhrui ) Met | Superior | 13 Sep 2021 | ||
Adapalene(0.1%) | ysxfcxgvwi(lklwmuyrnd) = hayitfnsut ilwrgfjymi (kobfodhrui ) Met |